For your info. I posted this twice b4.""From Egoli - Below is an...

For your info. I posted this twice b4.

""From Egoli - Below is an excerpt from a recent Interview with Dr Warwick Lamb, MD of Imugene.

EGOLI: You have predicted the global market for biological products to grow over the next 2-5 years, whilst growth in-feed antibiotic markets is expected to decline. How does Imugene plan on capturing this market ahead of its competitors such as Chemeq Limited?

We do not see Chemeq as a competitor for our existing range of products. The Chemeq product, as disclosed publicly, deals with a bacterial gastrointestinal disease of pigs and poultry. As it is not absorbed it cannot be used to treat, for example, respiratory infections and therefore the two companies are targeting different components within the pig and poultry market. The Imugene products have the ability to improve overall immunity to a range of diseases. Importantly any product in this field that prevents pigs or poultry from getting sick is advantageous to the producers. As the products target different diseases, the producers may well use both products together if they each individually protect against different diseases. Obviously the producers will focus on cost of each treatment and compare that with the economic gains achieved.""

Nick D